Cash, cash equivalents and investment securities were $341.0 million as of September 30, 2024. The company said it anticipates that cash, cash equivalents and investment securities as of September 30, 2024, combined with the projected revenues from BRIUMVI, will be sufficient to fund business based on current operating plan.
TG Therapeutics Says It Is On Path For Continued Growth Into End Of The Year And Into 2025 And Further Toward Long-term
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated